Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment

Kai Markus Schneider1,2,16, Antje Mohs1,16, Wenfang Gui1, Eric J. C. Galvez3, Lena Susanna Candels1, Lisa Hoenicke3, Uthayakumar Muthukumarasamy3, Christian H. Holland4,5, Carsten Elfers1, Konrad Kilic1, Carolin Victoria Schneider1,6, Robert Schierwagen7,8, Pavel Strnad1, Theresa H. Wirtz1, Hanns-Ulrich Marschall9, Eicke Latz10,11,12, Benjamin Lelouvier13, Julio Saez-Rodriguez4,5, Willem de Vos14,15, Till Strowig3, Jonel Trebicka7,8 & Christian Trautwein1

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, and therapeutic options for advanced HCC are limited. Here, we observe that intestinal dysbiosis affects antitumor immune surveillance and drives liver disease progression towards cancer. Dysbiotic microbiota, as seen in Nlrp6−/− mice, induces a Toll-like receptor 4 dependent expansion of hepatic monocytic myeloid-derived suppressor cells (mMDSC) and suppression of T-cell abundance. This phenotype is transmissible via fecal microbiota transfer and reversible upon antibiotic treatment, pointing to the high plasticity of the tumor microenvironment. While loss of Akkermansia muciniphila correlates with mMDSC abundance, its reintroduction restores intestinal barrier function and strongly reduces liver inflammation and fibrosis. Cirrhosis patients display increased bacterial abundance in hepatic tissue, which induces pronounced transcriptional changes, including activation of fibro-inflammatory pathways as well as circuits mediating cancer immunosuppression. This study demonstrates that gut microbiota closely shapes the hepatic inflammatory microenvironment opening approaches for cancer prevention and therapy.

1Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany. 2Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 3Helmholtz Centre for Infection Research, Braunschweig, Germany and Hannover Medical School, Hannover, Germany. 4Institute for Computational Biomedicine, Bioquant, Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Heidelberg, Germany. 5Joint Research Centre for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, Faculty of Medicine, Aachen, Germany. 6The Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. 7European Foundation for the Study of Chronic Liver Failure (EF-CLIF), 08021 Barcelona, Spain. 8Translational Hepatology, Department of Internal Medicine I, Goethe University Frankfurt, 60323 Frankfurt, Germany. 9Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 10Institute of Innate Immunity, Medical Faculty, University of Bonn, 53127 Bonn, Germany. 11Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01655, USA. 12German Center for Neurodegenerative Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01655, USA. 13Vaiomer SAS, Labège, France. 14Laboratory of Microbiology, Wageningen University, 6708 WE Wageningen, The Netherlands. 15Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, P.O. Box 63, 00014 Helsinki, Finland.

16These authors contributed equally: Kai Markus Schneider, Antje Mohs.

✉email: ctrautwein@ukaachen.de

https://doi.org/10.1038/s41467-022-31312-5
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the dominant cause of death in patients with compensated liver cirrhosis. HCC incidence keeps rising and despite recent advances, therapeutic options remain limited. HCC frequently arises in the context of chronic liver diseases (CLDs), with viral hepatitis B and C as well as alcoholic and non-alcoholic steatohepatitis (NASH) being the most common causes. These conditions are characterized by chronic hepatic inflammation and continuous liver damage leading to hepatocyte cell death, which prompts compensatory proliferation and precedes hepatocarcinogenesis. Therefore, a better understanding of these inflammatory processes is critical for developing new therapeutic strategies.

The NF-kB pathway is a core-signaling hub in hepatocytes that integrates the activity of various stress-related and inflammatory mediators. NF-kB is a transcription factor that can translocate to the nucleus and initiate gene transcription. Two different pathways can trigger its activation: the canonical pathway via cytoplasmic kinases such as TNFα, IL-1β, or TLR agonists and the noncanonical pathway, which is mainly important in B cells. The canonical pathway is mediated by phosphorylation of IkB by a high-molecular kinase complex, which is formed by two different catalytic IkB kinase 1 (IKK1 or alpha) and IKK2 (also IKKbeta) subunits as well as its regulatory subunit IkB kinase (IKK) subunit NF-kB essential modulator (NEMO or IKKγ). We and others have shown that blocking NF-kB activity in hepatocytes reduces inflammatory gene expression. However, this process at the same time results in impaired expression of anti-apoptotic genes promoting overshooting cell death and compensatory proliferation. Hence, conditional ablation of NEMO triggers spontaneous steatohepatitis and hepatocarcinogenesis in 12-month-old NEMOflohepa mice. These mice are a well-established model to study steatohepatitis progression towards HCC. In previous work, we have shown that activation of the canonical NF-kB pathway by experimental stimuli such as lipopolysaccharide (LPS) exacerbates this phenotype.

The liver receives 2/3 of its blood supply through the portal vein. Hence, the liver is continuously exposed to a vast amount of pathogen- and microbe-associated molecular patterns (PAMPs and MAMPs), which bind to pathogen recognition receptors (PRRs), trigger NF-kB activation in hepatocytes and non-parenchymal cells, thereby driving liver disease progression. This may critically shape the hepatic inflammatory microenvironment and fuel HCC development in the absence of NEMO.

In the diseased liver, senescence surveillance of pre-malignant hepatocytes by T cells limits liver cancer development by mounting specific immune responses. Based on their high expression of PRRs, Ly6C+CD11b+ F4/80low monocyte-derived suppressor cells (MDCSCs) are well equipped to sense MAMPs and expand upon PRR activation. Importantly, these cells can suppress the CD8+ cytotoxic T cell response and thus limit anti-tumor immunity.

Mice lacking the inflammasome sensor molecule NLRP6 develop a dysbiotic colitogenic microbiota composition when housed under specific pathogen-free (SPF) conditions. It has been shown that intestinal dysbiosis in mice deficient for NLRP6 promotes steatohepatitis via Toll-like receptor 4 (TLR4) and TLR9, a phenotype transmissible to co-housed wild-type (WT) mice. Conversely, we and others have shown that microbiota depletion using broad-spectrum antibiotics dampens experimental steatohepatitis. In recent clinical landmark studies, the presence of the gut microbiota and distinct bacteria were essential for an efficient anti-tumor immunotherapy. Studies have linked the presence of the bacterium Akkermansia muciniphila to favorable treatment response to immunotherapy in several solid malignancies, including HCC. Interestingly, murine studies show that oral supplementation with A. muciniphila reduces pro-inflammatory bacterial (LPS) and improves alcoholic liver disease.

While the link between intestinal dysbiosis and liver disease progression is well established, mechanisms by which gut microbiota and bacterial translocation shape the hepatic inflammatory milieu and affect anti-tumor immune surveillance remain incompletely understood. In human liver disease, intestinal dysbiosis is associated with intestinal barrier impairment, reduced microbiota diversity, overgrowth of certain unfavorable bacteria, and absence of beneficial communities. Since Nlrp6−/− mice mimic these hallmarks of intestinal dysbiosis, we used these mice as a tool to investigate how intestinal dysbiosis orchestrates the tumor microenvironment and affects the anti-tumor response during steatohepatitis progression. We hypothesized that Nlrp6−/−-mediated intestinal dysbiosis aggravates steatohepatitis and increases tumor burden in NEMOflohepa mice. In this work, we demonstrate that intestinal barrier impairment and bacterial translocation dynamically induce expansion of mMDSCs and suppression of CD8+ T cells, which can be blocked by antibiotic treatment and reversed by the targeted reintroduction of the commensal A. muciniphila. Similarly, in a cohort of cirrhosis patients, we observe a strong association between bacterial translocation and activation of fibro-inflammatory pathways that mediate cancer immunosuppression highlighting the close functional interaction between gut and liver during liver disease progression.

Results

Absence of NLRP6 augments liver disease progression in NEMOflohepa/Nlrp6−/− mice. The inflammasome sensor molecule NLRP6 has been identified as a key regulator of host–microbiota homeostasis of the intestine. To study the impact of Nlrp6−/−-mediated intestinal dysbiosis on steatohepatitis progression, we crossed NEMOflohepa with Nlrp6−/− mice. 52-week-old NEMOflohepa/Nlrp6−/− mice displayed a significantly higher tumor burden (Fig. 1a, b) and significantly increased liver-to-bodyweight ratio compared to NEMOflohepa mice (Supplementary Fig. 1a).

NEMOflohepa/Nlrp6−/− mice showed increased liver injury as indicated by higher serum levels of alanine aminotransferase (ALT) and glutamate dehydrogenase (GLDH), as well as alkaline phosphatase (AP) and bilirubin compared to NEMOflohepa mice (Fig. 1c, Supplementary Fig. 1b). In H&E-stained liver sections and immunohistochemistry staining of CD45, NEMOflohepa and NEMOflohepa/Nlrp6−/− mice showed pronounced immune cell infiltration (Fig. 1d). Liver fibrosis was evidenced by Sirius red (SR) staining as well as messenger RNA (mRNA) expression of the pro-inflammatory genes Tgβ and Collagen1a1 (Fig. 1d, e). Liver sections revealed that both NEMOflohepa and NEMOflohepa/Nlrp6−/− mice showed pronounced immune cell infiltration (Fig. 1d). However, the livers of NEMOflohepa/Nlrp6−/−− mice contained significantly increased numbers of CD11b+ cells compared to NEMOflohepa mice (Fig. 1f, Supplementary Fig. 1c). In contrast, CD8+ T cells were reduced upon loss of NLRP6 (Fig. 1f). Notably, loss of NLRP6 in WT mice was not sufficient to cause liver injury, inflammation, or fibrosis (Fig. 1, Supplementary Fig. 1).

As previously shown, in the absence of NEMO, activation of the canonical NF-kB pathway results in hepatocyte cell death due to the loss of anti-apoptotic gene expression. Therefore, we characterized how hepatic inflammation impacts cell death and compensatory proliferation in these mice. While mRNA expression of the pro-inflammatory cytokines Tnfa, Il6, Il1β as well as...
inflammasome components Caspase-1 and Nlrp3 remained unchanged in tumor tissue (Supplementary Fig. 1d), infiltration of myeloid CD11b+ was linked to higher gene expression levels of the pro-inflammatory genes Tnfa, Tlr4, Il1β, Nlrp3 and Ccl5 in whole liver tissue without macroscopic tumors (Fig.1g, Supplementary Fig. 1e). Previous reports suggest that absence of NLRP6 can result in overactivation of NLRP3. Whereas Nlrp3 expression was increased on the mRNA level, we could not confirm this on the protein level (Supplementary Fig. 1e, f). Moreover, Nlrp3 gene expression was unchanged in the early 13 weeks' time point, suggesting that overexpression of NLRP3 inflammasome in the absence of NLRP6 does not mediate the observed phenotype (Supplementary Fig. 1g). The inflammatory phenotype of 52-week-old mice was associated with pronounced pJNK activation in NEMOΔhepa/Nlrp6−/− mice (Fig. 1h) correlating with increased apoptotic hepatocyte cell death shown by cleaved Caspase3 staining and compensatory proliferation, based on Ki67 staining (Fig. 1i, j and Supplementary Fig. 1h).

Together, these data demonstrate that the absence of NLRP6 orchestrates the inflammatory response in the tumor microenvironment and drives liver disease progression towards fibrosis and cancer in NEMOΔhepa/Nlrp6−/− mice.

Loss of NLRP6 is associated with intestinal dysbiosis and barrier impairment in NEMOΔhepa/Nlrp6−/− mice. WT and Nlrp6−/− littermates from an initial heterozygous Nlrp6+/− breeding pair were used and separated after weaning to create independent WT and Nlrp6−/− lines, which were kept for at least 3 generations under specific pathogen-free (SPF) conditions to
allow the development of the dysbiotic Nlrp6−/− community. Subsequently, we employed male mice of these lines to investigate the impact of intestinal dysbiosis on steatohepatitis progression. Microbiota composition of 13-week- and 52-week-old NEMOΔhepa and NEMOΔhepa/Nlrp6−/− as well as WT and Nlrp6−/− control mice was analyzed in cecal samples using 16S rRNA gene amplicon sequencing.

First, the beta-diversity, the difference in the gut microbiota composition between mice, was compared based on Bray-Curtis dissimilarity among 13-week- and 52-week-old mouse groups. To evaluate the relative contribution of genotype (WT, Nlrp6−/−, NEMOΔhepa, NEMOΔhepa/Nlrp6−/−), cage, NEMO genotype (WT, Nlrp6−/− vs. NEMOΔhepa, NEMOΔhepa/Nlrp6−/−) as well as mouse line (Nlrp6−/−, NEMOΔhepa/Nlrp6−/− vs. WT, NEMOΔhepa) on the differences in microbiota composition between the groups, we performed permutational multivariate analysis of variance (ADONIS). Genotype, individual cage, NEMOΔhepa genotype and mouse line explained a significant proportion of total microbiota variability (genotype R² = 0.057, **p < 0.006; cage R² = 0.073, ***p < 0.004; NEMOΔhepa genotype R² = 0.079, **p < 0.002; mouse line R² = 0.16, ***p < 0.001) in 13-week-old mice (Fig. 2a). As expected, these analyses revealed a significant cage effect. We, therefore, expanded our ADONIS analyses by including genotype and cage with strata option set to "cage." Using this approach, genotype still explained a significant proportion of total microbiota variability (R = 0.296, p = 0.003).

Interestingly, although NEMOΔhepa and NEMOΔhepa/Nlrp6−/− were co-housed with their respective NEMOΔhepa (referred to as WT) and NEMOΔhepa/Nlrp6−/− littermate controls, conditional NEMO deficiency and the resulting steatohepatitis had a reproducible impact on microbiota composition. Importantly, beta-diversity analysis confirmed the development of a distinct microbiota in the Nlrp6−/− line, which explained the highest proportion of 16% of total microbiota variability (Fig. 2a).

We performed differential abundance analysis based on the negative binomial distribution (DESeq2) and linear discriminant effect size analysis (LEfSe) to dissect which specific bacteria account for the observed differences. These analyses revealed a strong relative increase in Muribaculum in NEMOΔhepa/Nlrp6−/− mice, while Verrucomicrobiaceae and several members of the family Lachnospiraceae were significantly reduced (Fig. 2b, c). Pairwise comparisons of all groups revealed a decrease of Roseburia and Lachnospiraceae in Nlrp6−/− mice compared to WT mice. Interestingly, Akkermansia was increased in NEMOΔhepa compared to WT littermates, which disappeared in NEMOΔhepa/Nlrp6−/− (Supplementary Fig. 2a–c).

These bacteria were absent in NEMOΔhepa/Nlrp6−/− both at the 13-weeks and 52-weeks time point, which discriminated NEMOΔhepa from NEMOΔhepa/Nlrp6−/− in LEfSe analyses (Fig. 2c, Supplementary Fig. 2d–f).

Next, we analyzed intestinal tissue sections of the different genotypes to explore the functional implications of the observed changes in microbiota composition. A. muciniphila is a well-known mucin-degrading bacterium. Its presence has been linked to thickening of mucus layers and intestinal barrier improvement. Therefore, we analyzed colonic mucus layers. Loss of Nlrp6 was associated with reduced thickness of colonic mucus layers, which was most pronounced in NEMOΔhepa/Nlrp6−/− mice (Supplementary Fig. 2g).

Intestinal barrier function was studied in more detail by performing immunofluorescence staining for the tight-junction (TJ) protein zonula occludens1 (ZO-1) in different parts of the intestine. ZO-1 expression was reduced in duodenum, jejunum, ileum, and colon of 52-week-old NEMOΔhepa/Nlrp6−/− mice compared to WT mice (Fig. 2d, Supplementary Fig. 2h). However, NEMOΔhepa/Nlrp6−/− mice displayed a further reduction of ZO-1, which was most pronounced in the ileum and colon. In line, occludin protein expression was found to be reduced in ileum and colon tissue lysates of 52-week-old NEMOΔhepa/Nlrp6−/− mice compared to NEMOΔhepa mice (Fig. 2e, f). Interestingly, disruption of the TJ barrier was associated with increased mRNA expression of inflammatory genes such as Il1β, Il18, Mcp1 and Cils and...
Fig. 2 Loss of NLRP6 results in intestinal dysbiosis and barrier impairment correlating with steatohepatitis activity and tumor burden. a Cecal microbiota composition of 13-week-old mice (WT (n = 8), Nlrp6−/− (n = 9), NEMOhepa (n = 13), NEMOhepa/Nlrp6−/− (n = 11)) was analyzed using 16S rRNA gene amplicon sequencing. Bar chart based on permutational multivariate analysis of variance (ADONIS) presenting the percentage of variance of the gut microbiota explained by the factors “Genotype” (R² = 0.057, **p < 0.006), “Cage” (R² = 0.073, **p < 0.004), “Nemo” (R² = 0.079, **p < 0.002), “Line”. Genotype - all included genotypes; Cage - individual cages; Nemo – WT & Nlrp6−/− mice vs. NEMOhepa & NEMOhepa/Nlrp6−/−; Line – WT & NEMOhepa vs. Nlrp6−/− & NEMOhepa/Nlrp6−/− (R² = 0.16, ***p < 0.001). b Analysis for differential abundance of microbiota via DESeq analysis of 13 weeks old NEMOhepa (n = 13) and NEMOhepa/Nlrp6−/− (n = 11) mice. c Linear discriminant analysis (LDA) of effect size (LEfSe) between NEMOhepa (n = 13) and NEMOhepa/Nlrp6−/− (n = 11). d Representative pictures of IF stainings of ZO-1 in ileum and colon of NEMOhepa, NEMOhepa/Nlrp6−/− and respective controls (WT, Nlrp6−/−). Nuclei were counterstained with DAPI, representative of 2 independent experiments; Scale bar: 100 μm. e, f Immunoblot analysis of ileum and colon protein extracts from 52-week-old mice for Occludin and β-actin as loading control of indicated genotypes, representative of 2 experiments. g RT-qPCR analysis of inflammatory mRNA expression (IL-1β, IL-18, TNFα, Mcp1, Cds1) in the ileum of NEMOhepa (n = 12) and NEMOhepa/Nlrp6−/− (n = 12) mice, unpaired t-test (IL-1β: NEMOhepa vs. NEMOhepa/Nlrp6−/−, 95% CI 0.0235–2.421, p = 0.046; IL-18: NEMOhepa vs. NEMOhepa/Nlrp6−/−, 95% CI 0.0293–0.7369, p = 0.035; TNFα: NEMOhepa vs. NEMOhepa/Nlrp6−/−, 95% CI 0.097–1.932, p = 0.032; Cds1: NEMOhepa vs. NEMOhepa/Nlrp6−/−, 95% CI 1.023–4.706, p = 0.0038). h In vivo intestinal permeability assessed by oral gavage of FITC-dextran. Rel. induction of FITC-dextran permeability in NEMOhepa (n = 6) and NEMOhepa/Nlrp6−/− mice (n = 4), unpaired t-test: NEMOhepa vs. NEMOhepa/Nlrp6−/−, 95% CI 1.010–1.615, p = 0.012), pooled data from 2 independent experiments. i Strong correlation (Spearman) of intestinal barrier function evidenced by FITC-dextran permeability with tumor number in NEMOhepa (blue dots) and NEMOhepa/Nlrp6−/− (red dots) mice (8 pairs), r = 0.96. All Data are presented as mean ± standard error of the mean (SEM; experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
increased infiltration of CD11b+ cells in ileal tissue (Fig. 2g, Supplementary Fig. 2i).

Together, intestinal dysbiosis upon lack of NLRP6 expression prompted disruption of the intestinal TJ barrier and increased inflammatory gene expression.

Intestinal permeability correlates with steatohepatitis activity and increased tumor burden. Next, we studied the functional implications of intestinal dysbiosis and intestinal barrier impairment in NEMOΔhepa/Nlrp6−/− mice. Here, we evaluated in vivo intestinal barrier function in a cohort of 52-week-old NEMOΔhepa and NEMOΔhepa/Nlrp6−/− mice and respective controls. Permeability of the intestinal barrier measured by 4000 kDa FITC-dextran was significantly increased in NEMOΔhepa/Nlrp6−/− compared to NEMOΔhepa controls (Fig. 2h). Strikingly, ALT levels and tumor number demonstrated a strong correlation with intestinal permeability (Fig. 2i, Supplementary Fig. 2j), indicating that intestinal barrier impairment exacerbates liver disease in NEMOΔhepa mice.

Loss of NLRP6 shapes the hepatic immune environment. Next, we addressed how NLRP6 orchestrates the hepatic immune environment at an early stage of cancer development. 13-week-old NEMOΔhepa/Nlrp6−/− mice displayed increased leukocyte infiltration, aggregated liver fibrosis evidenced by SR staining and increased hepatocyte proliferation supported by immunohistochemistry (IHC) staining for Ki67 (Fig. 3a, b, Supplementary Fig. 3a). More pronounced liver injury was reflected by significantly increased ALT, AST and GLDH levels in NEMOΔhepa/Nlrp6−/− mice compared to NEMOΔhepa mice (Fig. 3c, Supplementary Fig. 3c). In line, NEMOΔhepa/Nlrp6−/− mice displayed a significantly increased liver-to-body weight ratio compared to NEMOΔhepa mice (Supplementary Fig. 3d). Epithelial–mesenchymal transition during HCC development can be triggered by stellate cells. Indeed, we found increased stellate cell activation evidenced by aSMA staining in 13-week-old NEMOΔhepa/Nlrp6−/− compared to NEMOΔhepa mice (Supplementary Fig. 3e).

However, there was no evidence of increased hedgehog signaling activation in livers of NEMOΔhepa/Nlrp6−/− mice (Supplementary Fig. 3f).

Intestinal dysbiosis and barrier impairment promote translocation of MAMPs via the portal vein into the liver, where they activate innate immune response mediated by pathogen recognition receptors (PRRs). NEMOΔhepa/Nlrp6−/− showed significantly increased infiltration of CD45+ leukocytes compared to NEMOΔhepa livers (Fig. 3d, e). Flow cytometry analyses (FACS) (gating strategy—Supplementary Fig. 4a, b) of whole liver lysates revealed significantly increased infiltration of myeloid-derived suppressor cells (defined as CD45+Ly6G−/Gr1hi) as well as CD11b+Ly6G+ myeloid cells in NEMOΔhepa/Nlrp6−/− mice compared to NEMOΔhepa mice (Fig. 3f, Supplementary Fig. 4c). Strikingly, we found a strong correlation of mMDSC abundance with ALT levels suggesting their role as mediators of liver injury in NEMOΔhepa mice (**p < 0.0001, r = 0.8087) (Fig. 3g).

Besides being well equipped with PRRs to trigger an inflammatory response upon exposure to MAMPs29, mMDSCs are defined by their suppressive capacity on T cells in the context of cancer development. Interestingly, NEMOΔhepa/Nlrp6−/− mice displayed a strong reduction in cytotoxic CD8+ T cells (defined as CD45+CD3+CD8+) and CD4+ T cells (defined as CD45+CD3+CD4+) (Fig. 3h, Supplementary Fig. 4d). Consistent with suppression of T cells, mMDSC abundance was inversely correlated with cytotoxic T cells (**p = 0.0040, r = −0.5767) (Fig. 3i). Other immune myeloid and lymphoid immune cell subsets, including Kupffer cells, NK/NKT cells, and B cells remained unchanged (Supplementary Fig. 4e–h). We observed increased expression of the common M2 marker Arg1, while the M1 marker Nos2 was decreased in NEMOΔhepa/Nlrp6−/− mice, pointing towards a pro-tumorigenic microenvironment in these mice (Supplementary Fig. 4i).

To further characterize these mice and explored their inhibitory capacity on T cells by performing in vitro assays (Supplementary Fig. 5b). T cells were isolated from WT and Nlrp6−/− spleens, labeled with CFSE, stimulated with CD3/CD28, and co-cultured with granulocytic MDSC (defined as CD45+Ly6G+Gr1hi) or mMDSCs (defined as CD45+Ly6G−Gr1hi) isolated from NEMOΔhepa or NEMOΔhepa/Nlrp6−/− livers by magnetic-activated cell sorting (MACS). We did not observe baseline differences in T cell proliferation between WT and Nlrp6−/− mice (Supplementary Fig. 5c, d). Moreover, T cell proliferation remained unaffected upon co-culture with hepatic gMDSCs from either genotype (Supplementary Fig. 5c, d). However, mMDSCs strongly suppressed CD8+ T cell proliferation, most pronounced upon co-culture with mMDSCs isolated from NEMOΔhepa/Nlrp6−/− mice (Fig. 3j).

Together, these data demonstrate that intestinal dysbiosis in NEMOΔhepa/Nlrp6−/− mice is associated with an expansion of mMDSCs, which had a stronger suppressive capacity when isolated from NEMOΔhepa/Nlrp6−/− than from NEMOΔhepa mice.

Microbiota depletion reshapes hepatic inflammatory microenvironment and ameliorates steatohepatitis. To test whether microbiota shapes the hepatic inflammatory response in NEMOΔhepa/Nlrp6−/− livers, we treated 8-week-old mice until week 13 using an established combination of non-absorbable broad-spectrum antibiotics (ABx). As previously described31, this treatment led to an almost complete microbiota depletion evidenced by enlarged caeca similar to germ-free mice as well as significantly reduced total bacterial DNA content in fecal samples evidenced by qPCR assays using primers for all bacteria (Supplementary Fig. 6a). Strikingly, after ABx treatment liver transaminase levels of NEMOΔhepa/Nlrp6−/− mice were similar to NEMOΔhepa mice and significantly reduced compared to non-treated mice (Fig. 4a). Importantly, ABx treatment resulted in a significant reduction of mMDSC as evidenced by FACS and also reflected in a lower number of CD11b+ cells in IF staining (Fig. 4b, c). Conversely, ABx treatment resulted in an expansion of CD8+ T cells and CD4+ T cells, which almost reached the level as found in NEMOΔhepa livers (Fig. 4b, Supplementary Fig. 6b).

Immune phenotype of NEMOΔhepa/Nlrp6−/− mice is transmissible to NEMOΔhepa mice via FMT and involves TLR4 signaling. Microbiota depletion using ABx ameliorated liver injury, dampened mMDSC infiltration and restored cytotoxic T cell abundance in NEMOΔhepa/Nlrp6−/− mice (Fig. 4b).

To further test the pathogenic relevance of Nlrp6−/− microbiota, we performed fecal microbiota transfer (FMT) of NEMOΔhepa/Nlrp6−/− mice into NEMOΔhepa mice. In accordance with successful FMT, NEMOΔhepa receiving NEMOΔhepa/Nlrp6−/− microbiota formed a distinct cluster that clustered close to NEMOΔhepa/Nlrp6−/− FMT-Donors in NMDS ordination...
Fig. 3 mMDSC drive steatohepatitis activity in NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} mice. a Representative pictures of H&E-stained liver sections and immunohistochemical staining of Ki67 stained liver sections of 13-week-old WT, Nlrp6\textsuperscript{−/−}, NEMO\textsuperscript{hepa}, and NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} livers; Scale bar: 100 μm. b Histological quantification of Ki67\textsuperscript{+} cells per viewfield (WT n = 18, Nlrp6\textsuperscript{−/−} n = 12, NEMO\textsuperscript{hepa} n = 36, NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} n = 35, one way ANOVA, Tukey’s multiple comparison test; Ki67: WT vs. NEMO\textsuperscript{hepa}, 95% CI −34 to −22, p < 0.0001; WT vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −40 to −28, p < 0.0001; NEMO\textsuperscript{hepa} vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −11.54 to −1.67, p = 0.0039). c Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of 13-week-old NEMO\textsuperscript{hepa} (n = 13), NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} (n = 10) and respective controls (WT (n = 9), Nlrp6\textsuperscript{−/−} (n = 8), one way ANOVA, bonferroni’s multiple comparison test: ALT: WT vs. NEMO\textsuperscript{hepa}, 95% CI −1.123 to −344.4, p < 0.0001; WT vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −1700 to −875.6, p < 0.0001; NEMO\textsuperscript{hepa} vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −931.8 to −177.0, p = 0.0002; AST: WT vs. NEMO\textsuperscript{hepa}, 95% CI −764 to −210, p < 0.0001; WT vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −1147 to −588, p < 0.0001; NEMO\textsuperscript{hepa} vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −1.735 to −0.2338, p < 0.0001). d Representative pictures and quantification of immunohistochemical (IHC) staining of CD45 stained liver sections of 13-week-old mice (WT (n = 4), Nlrp6\textsuperscript{−/−} (n = 3), NEMO\textsuperscript{hepa} (n = 13), and NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} (n = 8), one way ANOVA, Tukey’s multiple comparisons test, WT vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −2855 to −8097, p < 0.001; NEMO\textsuperscript{hepa} vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −7.5 to −0.8, p = 0.007); Scale bar: 200 μm. e Flow cytometry analysis of monocytic myeloid-derived suppressor cells (mMDSC) isolated from whole liver of 13-week-old NEMO\textsuperscript{hepa} (n = 12), NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} (n = 11) and respective controls (WT (n = 7), Nlrp6\textsuperscript{−/−} (n = 8) one way ANOVA, Sidak’s multiple comparison test: WT vs. NEMO\textsuperscript{hepa}, 95% CI −101.1 to −2.7, p = 0.0002; Nlrp6\textsuperscript{−/−} vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −118 to −4.2, p < 0.0001; NEMO\textsuperscript{hepa} vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI −7.5 to −0.8, p = 0.009). g The percentage of mMDSCs of CD45\textsuperscript{+} living cells strongly correlates with ALT levels in NEMO\textsuperscript{hepa} and NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} mice (Spearman, 23 pairs). h Flow cytometry analysis of CD3\textsuperscript{+}CD8\textsuperscript{+} cytotoxic T cells isolated from whole liver of 13-week-old NEMO\textsuperscript{hepa} (n = 14), NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} (n = 10) and respective controls (WT (n = 9), Nlrp6\textsuperscript{−/−} (n = 9), one way ANOVA; Sidak’s multiple comparison test: WT vs. NEMO\textsuperscript{hepa}, 95% CI −12.4 to −8.0, p < 0.0001; NEMO\textsuperscript{hepa} vs. NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−}, 95% CI 5.3 to −9.5, p < 0.0001; NEMO\textsuperscript{hepa}/Nlrp6\textsuperscript{−/−} vs. NEMO\textsuperscript{hepa}, 95% CI 0.8 to 9.5, p < 0.009. i Percentage of mMDSCs of CD45\textsuperscript{+} living cells and CD8\textsuperscript{+} cytotoxic T-cells is inversely correlated (Spearman 18 pairs). j In vitro T-cell proliferation assay. T cells were co-cultured with granulocytic MDCSCs or monocytic MDCSCs, representative of 2 experiments. All data are presented as the mean ± standard error of the mean (SEM). Experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
analysis based on Bray–Curtis dissimilarity (Supplementary Fig. 6c). Microbiota transfer resulted in a shift of NEMOΔhepa microbiota along NMDS axis 1. DESeq2 as well as LESe analyses comparing NEMOΔhepa mice with and without FMT revealed that this shift was mainly driven by differential abundance of A. muciniphila (Fig. 4d, Supplementary Fig. 6d). Strikingly, upon FMT all recipient NEMOΔhepa mice were lacking A. muciniphila (Supplementary Fig. 6e), and only one differential OTU (OTU23_ambiguous_taxa) was observed in LESe analyses comparing NEMOΔhepa FMT-recipient with NEMOΔhepa/Δhepa−/− FMT-Donors, further supporting successful microbiota transfer.

FMT resulted in a significant increase in liver transaminases AST and ALT in NEMOΔhepa animals (Fig. 4e). Interestingly, FMT of NEMOΔhepa/Δhepa−/− microbiota prompted an increase in absolute numbers of CD45+ hepatic leukocytes, significant expansion of hepatic mMDSCs and suppression of cytotoxic T cells in recipient NEMOΔhepa mice (Fig. 4f–h, Supplementary Fig. 6f).

Since intestinal dysbiosis in NEMOΔhepa/Δhepa−/− mice impairs intestinal barrier function and thus promotes activation of PRRs, we tested whether TLR4 is involved in mediating mMDSCs expansion upon FMT of NEMOΔhepa/Δhepa−/− microbiota. We generated NEMOΔhepa/Δhepa−/− mice and transferred microbiota of NEMOΔhepa or NEMOΔhepa/Δhepa−/− microbiota into recipient littermates. Strikingly, in NEMOΔhepa/Δhepa−/− the FMT of NEMOΔhepa/Δhepa−/− microbiota did not increase liver injury; serum AST and ALT levels and mMDSC abundance remained unchanged compared to control mice treated with NEMOΔhepa microbiota (Fig. 4i, j).

Consistent with the involvement of TLR4 in mMDSC expansion, both 8- and 52-week-old NEMOΔhepa/Δhepa−/− displayed a reduced abundance of these cells (Supplementary Fig. 6g). This observation was associated with significantly reduced liver transaminase levels (Supplementary Fig. 6h, i), reduced cell death as well as proliferation, and a markedly reduced tumor burden in 52-week-old mice (Supplementary
Fig. 4 Microbiota modulation reshapes the hepatic inflammatory microenvironment in NEMO<sup>Δhepa</sup> livers. a NEMO<sup>Δhepa</sup> and NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> mice were treated with broad-spectrum antibiotics (ABx) for 8 weeks and then week 13. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of NEMO<sup>Δhepa</sup> (n = 12) and NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> (n = 11) or untreated (n = 10) mice were measured at week 5. b Flow cytometry analysis of monocyte myeloid-derived suppressor cells (mMDCS) and CD3<sup>+</sup>CD8<sup>+</sup> T-cells were stained with DAPI, representative of 2 experiments. Scale bar: 100 μm. c,d NEMO<sup>Δhepa</sup> or NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> mice were treated with ABx, 95% CI: 316.0 to 405.4, p = n.s.; NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> vs. NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> + ABx, 95% CI: 277.8 to 1033, p = 0.0004; AST: NEMO<sup>Δhepa</sup> vs. NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> + ABx, 95% CI: 8.094 to 552.3, p = 0.047; NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> vs. NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> + ABx, 95% CI: 399.3 to 120.6, p = n.s. b Flow cytometry analysis of monocyte myeloid-derived suppressor cells (mMDCS) and CD3<sup>+</sup>CD8<sup>+</sup> T-cell populations were stained with DAPI, representative of 2 experiments. Scale bar: 100 μm. 

Fig. 6j-l). Interestingly, reduced mMDSC abundance in NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> mice was associated with an increase in CD3<sup>+</sup>CD4<sup>+</sup> T cells (Supplementary Fig. 6m).

To determine whether this immunologic phenotype was mediated by hematopoietic or parenchymal cells, we performed bone marrow transplantation experiments. Bone marrow chimeric NEMO<sup>Δhepa</sup> mice receiving Tlr4<sup>−/−</sup> donor bone marrow demonstrated a significant 6-fold reduction in mMDSC abundance compared to NEMO<sup>Δhepa</sup> mice receiving WT control bone marrow pointing towards a role of TLR4 in hematopoietic cells for the observed phenotype (Supplementary Fig. 6n).

Together, these data demonstrate that the immune phenotype of NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> mice is transmissible to NEMO<sup>Δhepa</sup> mice upon FMT. Precisely, TLR4 signaling in hematopoietic cells augments mMDSC infiltration and promotes steatohepatitis progression towards HCC.

Specific alterations of gut microbiota correlate with liver disease phenotype in NEMO<sup>Δhepa</sup> mice. Intestinal microbiota of NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> was significantly different from NEMO<sup>Δhepa</sup> mice after 13 and 52 weeks. Interestingly, microbiota modulation immediately reshaped the hepatic inflammatory microenvironment. In a final experiment, we, therefore, aimed to explore which specific changes in microbiota may modulate liver disease activity in NEMO<sup>Δhepa</sup> mice. LESe analysis showed a major relative reduction in A. muciniphila in 13- and 52-week-old NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> compared to NEMO<sup>Δhepa</sup> mice. This bacterium A. muciniphila was significantly reduced in 13- and 52-week-old NEMO<sup>Δhepa</sup>/Nlrp6<sup>−/−</sup> as well as NEMO<sup>Δhepa</sup> mice receiving FMT (Fig. 2b, Supplementary Fig. 6d). Moreover, in NEMO<sup>Δhepa</sup> microbiota relative abundance of A. muciniphila inversely correlated with hepatic mMDSC abundance (Spearman’s r = 0.8508, p = 0.0005) as well as serum ALT and GLDH levels highlighting the relevance of these bacteria in mediating the observed phenotype (Fig. 5a, Supplementary Fig. 7a). Hence, we tested our hypothesis that the transfer of A. muciniphila ameliorates liver disease in NEMO<sup>Δhepa</sup> mice. 8-week-old NEMO<sup>Δhepa</sup> littermate mice were gavaged orally with 2·10<sup>8</sup> colony forming units (CFUs) A. muciniphila or anaerobic PBS 3 times a week for 5 weeks (Fig. 5b). Successful microbiota transfer was confirmed by RT-qPCR and 16S RNA gene amplicon sequencing of stool samples before and after 5 weeks of gavage (Fig. 5c, Supplementary Fig. 7b, c). Interestingly, AKK treatment did not only increase the abundance of this specific bacterium but resulted in a significant shift in microbiota composition as reflected in distinct clustering in principal coordinates analysis (PCoA) (Fig. 5c, Supplementary Fig. 7d). Treatment with A. muciniphila explained a large proportion of total microbiota variability observed in these mice (R<sup>2</sup> = 0.403, *p < 0.05).

LESe analysis revealed a reduction of the phylum Bacteroides and expansion of Akkermansia (Fig. 5d). In DESeq2 analyses, Akkermansia supplementation also led to an increase in the abundance of Lachnospiraceae and Blautia, which was associated with an increase in overall microbiota richness (Supplementary Fig. 7e). Increased abundance of the genus A. muciniphila in NEMO<sup>Δhepa</sup> mice after transfer could also be confirmed using AldEx2 (Supplementary Table 1). In line with these data, we observed a significant expansion of the colonic mucus layers and increased ZO-1 expression in NEMO<sup>Δhepa</sup> mice gavaged with A. muciniphila compared to PBS treated control mice (Fig. 5e, f, Supplementary Fig. 7f).

Consistent with these data, western blot analyses of colon tissue lysates revealed a significant and strong increase in occludin protein levels upon A. muciniphila administration (Fig. 5g, Supplementary Fig. 7g). Strikingly, serum levels of liver injury...
**Fig. 5** *Akkermansia muciniphila* supplementation ameliorates liver disease in NEMOΔhepa mice. 

**a** Inverse correlation (Spearman, 13 pairs) between mMDSC and abundance of *A. muciniphila* (AKK) in caeca of NEMOΔhepa mice. **b** Experimental setup: 8-week-old NEMOΔhepa mice were gavaged either with 2.1×10^8 CFU AKK or sterile anaerobic PBS for 5 weeks. **c** Principle Coordinates Analysis (PCoA) plot of microbiota (cecal content, stool) of NEMOΔhepa mice (n = 4) before and after AKK treatment. **d** Results of LDA effect size (LEfSe) of cecal microbiota of NEMOΔhepa mice (n = 4) before and after AKK treatment at bacterial taxa level. **e** Representative pictures of immunofluorescence staining of MUC2 in colon of NEMOΔhepa mice treated with PBS or AKK. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 μm. **f** Representative pictures of immunofluorescence staining of ZO-1 in ileum and colon of NEMOΔhepa mice treated with PBS or AKK. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 μm. **g** Immunoblot analysis of colon protein extracts from NEMOΔhepa mice either treated with PBS or AKK for 5 weeks for occludin and β-actin as loading control, representative of 2 experiments. **h** Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of NEMOΔhepa mice either treated with PBS (n = 6) or AKK (n = 8) for 5 weeks, unpaired t-test: ALT: NEMOΔhepa AKK vs. NEMOΔhepa PBS, 95% CI −835.1 to −312.4, p < 0.0001; AST: NEMOΔhepa AKK vs. NEMOΔhepa PBS, 95% CI −395.6 to −431.0, p < 0.0001. **i** Representative pictures of H&E-stained liver sections and immunofluorescence staining for CD11b in either PBS (n = 6) or AKK (n = 8) treated NEMOΔhepa mice. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 μm. **j** RT-qPCR analysis of inflammatory and fibrotic mRNA expression (TGFβ, Col1α1, Mcp-1, Tlr4) in whole liver of NEMOΔhepa mice treated with PBS (n = 6) or AKK (n = 8) for 5 weeks, unpaired t-test, TGFβ: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.4722 to −0.03676, p = 0.026; Col1α1: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −1.023 to −0.1061, p = 0.019; Mcp-1: NEMOΔhepa AKK (n = 7) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.5069 to −0.1172, p = 0.0048; Tlr4: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.4238 to −0.07837, p = 0.008. All data are presented as the mean ± standard error of the mean (SEM) and considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.001 (****), respectively. Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
markers namely ALT, AST, LDH and GLDH were significantly decreased in NEMO<sup>−/−</sup>hepa mice gavaged with A. muciniphila compared to PBS treated controls (Fig. 5h, Supplementary Fig. 7h). This phenotype was reflected in histology: A. muciniphila treatment resulted in reduced liver fibrosis and significantly less leukocyte infiltration as evidenced by CD45 and CD11b staining (Fig. 5i, Supplementary Fig. 7i, j). In line, mRNA expression of fibro-inflammatory genes was significantly reduced in A. muciniphila treated NEMO<sup>−/−</sup> mice (Fig. 5j).

Finally, we asked whether liver disease progression could even be improved in the Nlrp6<sup>−/−</sup> dysbiosis model. A. muciniphila administration reduced liver injury in NEMO<sup>−/−</sup>/Nlrp6<sup>−/−</sup> mice compared to PBS treated NEMO<sup>−/−</sup> mice (Supplementary Fig. 8a, b), which was associated with significantly reduced infiltration of myeloid CD11b<sup>+</sup> cells and lower liver fibrosis evidenced by Sirius red staining (Supplementary Fig. 8c, d). Together these data demonstrate that continuous A. muciniphila supplementation can reduce liver injury, inflammation, and fibrosis even in the presence of host-derived factors that promote dysbiosis such as NLRP6 deficiency.

Bacterial translocation is higher in cirrhosis patients and shapes the hepatic transcriptomic landscape. We next tested if our observation in mice may also applies to humans. We therefore collected snap frozen liver tissue from patients with advanced liver cirrhosis of mixed etiology that underwent liver transplantation (n = 43) and controls undergoing other abdominal surgery (n = 12) (Supplementary Table 2). Small specimen from the same tissue region were cut and further processed for mRNA and isolation of bacterial DNA. Next, we analyzed hepatic bacterial DNA abundance using 16S rRNA gene amplicon sequencing in a strictly controlled environment using a stringent contamination-free method. Next, we isolated bacterial DNA. Next, we analyzed hepatic bacterial DNA abundance using 16S rRNA gene amplicon sequencing in a strictly controlled environment using a stringent contamination-free method. In line, mRNA expression and transcription factor activity of thymocyte selection encoded high mobility group box (TOX), interferon regulatory factor 4 (IRF4) and REL and BACH2—which instruct T cell exhaustion and immune suppression in human cancer—strongly correlated with 16S rRNA gene abundance (Fig. 5f). Conversely, transcription factor expression and activity of TOX3—which has been associated with a activated T cell state—was among the 5 TF with the strongest inverse correlation with 16S rRNA abundance (Supplementary Fig. 9g).

Activation of an innate immune response upon exposure with MAMPs and PAMPs depends on sensing via PRRs. Interestingly, the expression of several PRRs such as EGFR, MAPK, P53, PI3K, and WNT to be significantly associated with liver disease progression towards cirrhosis and HCC.

Bacterial translocation shapes the inflammatory microenvironment and promotes expression of T cell exhaustion markers in liver cirrhosis. Based on our murine data, we next specifically investigated the impact of bacterial translocation on the hepatic inflammatory milieu in human liver cirrhosis. To this end, we computationally dissected the hepatic cellular landscape based on gene expression profiles using xCell<sup>38</sup>. Cirrhotic livers showed enrichment for overall immune and stroma cells relected in the microenvironment, stroma, and immune xcell-scores, while the hepatocyte score was found to be relatively reduced (Fig. 6d). Interestingly, higher 16S RNA gene abundance was associated with increased CD8<sup>+</sup> T cells, NKT cells, central memory CD4<sup>+</sup> and regulatory T cells, the latter of which have been implicated in tumor immunosuppression (Fig. 6d, Supplementary Table 5).

Several immune checkpoint genes including PDCD1 encoding for PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) showed a strong correlation with 16S RNA abundance (PDCD1: Spearman-R = 0.59, P = 0.0007; CTLA4: Spearman-R = 0.66, P < 0.0001, Fig. 6c, f). In line with these findings, gene expression and transcription factor activity of thymocyte selection encoded high mobility group box (TOX), interferon regulatory factor 4 (IRF4) and REL and BACH2—which instruct T cell exhaustion and immune suppression in human cancer—strongly correlated with 16S rRNA gene abundance (TOX: Spearman-R = 0.66, P < 0.0001; IRF4: Spearman R = 0.65, P < 0.0001, Fig. 6g, Supplementary Fig. 9e). Conversely, transcription factor expression and activity of TOX3—which has been associated with an activated T cell state—was among the 5 TF with the strongest inverse correlation with 16S rRNA abundance (Supplementary Fig. 9g).

Activation of an innate immune response upon exposure with MAMPs and PAMPs depends on sensing via PRRs. Interestingly, the expression of several PRRs such as NOD1, NLRP3, and TLR2 all correlated with bacterial translocation (Supplementary Fig. 9h). MDSCs are important sensors of MAMPs and PAMPs and may dampen T cell function. Expression levels of the MDSC markers colony-stimulating factor receptor2a (CSFR2A) and interleukin1-receptor2 (IL1R2) both demonstrated a strong correlation with 16S rRNA gene abundance (Supplementary Fig. 9i).

Together, these data show that bacterial translocation in cirrhotic patients is strongly associated with fibro-inflammatory pathways as well as TF activation linked to immunosuppression and T cell exhaustion.

Discussion

In the last decade, the gut-liver axis and gut microbiota have emerged as cornerstones in the pathogenesis of chronic liver diseases<sup>11,42–44</sup>. Our present study defines intestinal barrier impairment and bacterial translocation as key mechanisms that shape the hepatic inflammatory microenvironment and fuel liver disease progression towards cirrhosis and HCC.

Chronic diseases, environmental and dietary factors associated with modern western lifestyles as well as medication have been found to contribute to intestinal dysbiosis. These factors trigger qualitative and quantitative changes in bacterial communities and directly affect the systemic inflammatory status<sup>25,47</sup>. As the liver is constantly exposed to a vast amount of microbiota-derived products from the gut via the portal vein, changes in intestinal homeostasis particularly impact liver physiology<sup>11,46</sup>. 

**NATURE COMMUNICATIONS** | https://doi.org/10.1038/s41467-022-31312-5 | www.nature.com/naturecommunications
Mouse models represent a suitable tool to functionally study mechanisms of gut-liver interaction allowing comprehensive mechanistic investigations. For our mechanistic studies, we decided to study chronic liver disease progression in NEMOΔhepa mice lacking the inflammasome sensor molecule NLRP6, which has been identified as an important regulator of host-microbial crosstalk at the gut mucosal surface. NEMOΔhepa mice develop spontaneous steatohepatitis, liver fibrosis and finally HCC. Interestingly, microbiota of NEMOΔhepa was different from WT mice and these mice demonstrated reduced barrier function compared to WT littermate controls. The mechanisms by which hepatic loss of NEMO impairs intestinal barrier will be
subject to future studies and could be mediated by changes in bile acid composition or low-grade systemic inflammation. Although the loss of NLRP6 NEMO other IKK components have not been described in human HCC, this mouse model nicely reflects essential mechanisms of human liver disease progression and allowed us to study the impact of intestinal dysbiosis induced by loss of NLRP6 on liver disease progression.

In our study, changes in gut microbiota composition of NEMOΔhepa/Nlrp6−/− mice translated into impaired intestinal barrier function strongly correlating with markers of steatohepatitis activity as well as tumor burden. Interestingly, microbiota of NEMOΔhepa/Nlrp6−/− mice was significantly different from NEMOΔhepa mice. Specifically, Nlrp6 deletion was associated with an increased abundance of the pathobiont Muribaculum, while Akkermansia muciniphila was absent. Several human, as well as murine studies, have demonstrated health benefits of A. muciniphila by promoting intestinal barrier function via regulation of intestinal mucus layers and acetate and propionate production.22,23,28,47. Interestingly, loss of A. muciniphila has recently been described in patients with early HCC.48

To address whether the observed phenotype was caused by altered microbiota, we performed microbiota modulation experiments. Interestingly, the phenotype of NEMOΔhepa/Nlrp6−/− mice was transmissible via FMT of the unfavorable NEMOΔhepa/Nlrp6−/− community and reversible upon AXB treatment. NLRP6 deficiency in NEMOΔhepa mice or transfer of NEMOΔhepa/Nlrp6−/− microbiota transfer into NEMOΔhepa mice triggered a pronounced infiltration of hepatic myeloid cells (defined as CD11b+Ly6G+Gr1hi). We termed these cells as mMDSCs based on surface marker expression and after confirming their in vitro suppressive capacity on T cell proliferation. These dynamic changes were linked to the reduced abundance of T cells pointing towards the high cellular plasticity of the hepatic inflammatory microenvironment related to microbiota. Several studies have highlighted the anti-tumor activity of CD8+ T cells in HCC49,50; however, this is dependent on their phenotype and tissue microenvironment.51 They may also promote liver damage and progression towards HCC.52 Future CD8+ T cell depletion experiments could help to establish causality in this model. HCC development Kupffer cells and macrophages may undergo phenotypic changes and promote a pro-tumorigenic microenvironment.53 In our study we did not observe changes in Kupffer cell abundance, however, hepatic gene expression pointed towards an M2-skewed microenvironment. Regulatory T cells can be programmed in the gut and might exert their immunosuppressive function in the liver.54,55 While not being the focus of our study, future studies on this mechanism might advance our understanding of gut-mediated immune modulation during HCC development.

Based on previous data and the landmark paper by Dapito et al., we hypothesized that PRR signaling and especially TLR4 may be an important orchestrator of this response.56 Interestingly, NEMOΔhepa/Tlr4−/− mice displayed a reduced abundance of MDSCs and an increase in CD4+ T cells, which was linked to a lower tumor burden at 52 weeks. Accordingly, transfer of the dysbiotic NEMOΔhepa/Nlrp6−/− community failed to induce an expansion of mMDSCs in NEMOΔhepa/Tlr4−/− mice. In line with previous data, these results clearly suggest an involvement of TLR4 mediated PRR signaling in MDSC expansion.57 However, we cannot exclude that other PRRs, as well as other microbiota dependent pathways, may form equally important circuits directing the inflammatory response in the cirrhotic liver.58

Almost all cases of HCC arise in the context of cirrhosis, where chronic inflammation mediated by innate and adaptive immune responses drives disease progression.59 However, immunosurveillance by T and B cells can also limit hepatocarcinogenesis.12 In this context, the interplay between T cells and MDSCs is critical as MDSCs accumulation may induce T cell exhaustion promoting HCC progression.60,61 Hence, immune-mediated mechanisms are essential during liver disease progression towards malignant transformation and dissecting their different functions will define novel therapeutic options. Gut microbiota can direct hepatic immunity in multiple ways via MAMPs, microbial metabolites, bile acids as well as short chain fatty acids.62,63

In patients, assessing the intestinal barrier as well as bacterial translocation and its molecular impact on the liver are challenging as there are no good non-invasive serum markers of barrier dysfunction and hepatic inflammation. While a series of studies have linked altered gut microbiota composition and metagenomic profiling to clinical and histopathological cirrhosis phenotypes,64,65 data on whether these changes direct the hepatic inflammatory response or modulate the transcriptional landscape have not been available yet.24 Based on our murine models, we hypothesized that bacterial translocation may also shape the hepatic inflammatory microenvironment in patients with advanced liver cirrhosis. We, therefore, assessed bacterial translocation by an established protocol of 16s rRNA analysis from liver tissue, quantified total bacterial DNA content, performed 16s rRNA gene amplicon sequencing and correlated these data with transcriptomic data generated from the same tissue specimens. In line with our murine data, bacterial translocation strongly correlated with fibro-inflammatory transcriptional pathways in human liver cirrhosis implicating bacterial translocation as a driver of liver disease progression.

A recent clinical study compared 20 Child Pugh A cirrhotic NAFLD patients with and without early HCC.48 The authors found increased serum markers of intestinal inflammation (calprotectin) as well as permeability (ZO-1 and LPS) in cirrhosis patients vs. healthy controls. Interestingly, impaired barrier function was associated with reduced abundance of Akkermansia in NAFLD cirrhotic patients compared with controls and correlated with circulating mMDSCs in the HCC group.

Our functional data in the NEMOΔhepa mouse model are in line with these findings. Moreover, in NEMOΔhepa mice we observed profound changes of mMDSC and T cell abundance after short-
term microbiota modulation. Additionally, supplementation with the single bacterium *Akkermansia muciniphila* improved intestinal barrier function, reduced infiltration of MDSCs and dampened steatohepatitis activity. Together, these data call for further studies to assess therapeutic supplementation with *Akkermansia* in HCC patients. The ideal study would involve the collection of liver biopsies as well as microbiota specimens, which would allow correlation of intestinal microbiota with hepatic 16S rRNA gene abundance and the hepatic transcriptional profile.

In a recent clinical trial daily supplementation of *A. muciniphila* for 3 months was well-tolerated, improved insulin sensitivity and blood lipid profiles in obese insulin-resistant individuals. Similar to our murine data, modulating gut microbiota has the potential to reshape the hepatic inflammatory milieu in HCC patients, a hypothesis that is also inspired by a series of studies highlighting the role of microbiota in immune checkpoint therapy. Here, recent studies have linked *Akkermansia* abundance to favorable treatment responses, while broad spectrum antibiotic intake before therapy which induces intestinal dysbiosis – impaired treatment responses. While this strong immune mediated pathogenesis highlights HCC as a particularly interesting target for immunotherapies, characteristics of the hepatic tumor microenvironment define a high barrier of resistance to immunotherapy. Although the cirrhotic liver tissue they studied may not specifically reflect the HCC microenvironment, the observed correlations between hepatic 16S rRNA abundance and expression of fibro-inflammatory pathways, genes involved in cancer immunosuppression as well as MDSCs, T cell exhaustion, and PRR-signaling are likely also relevant in disease progression towards HCC. It is tempting to speculate that hepatic 16S RNA gene abundance may serve as a biomarker of intestinal barrier impairment and dysbiosis that helps to predict treatment response to immune therapies and identify patients that could benefit from microbiota modulation. PCR-based measurements could be easily implemented in standard clinical biopsy workflows. A limitation of our study is that functional microbiota modulation studies were only performed in mice—additional studies in humans are needed. Based on our microbiota analyses as well as extensive literature on *A. muciniphila* and intestinal homeostasis, we focused our functional microbiota analyses as well as extensive literature on functional microbiota modulation studies were only performed in standard clinical biopsy work. Helps to predict treatment response to immune therapies and speculate that hepatic 16S rRNA gene abundance may serve as a relevant in disease progression towards HCC. It is tempting to consider whether the transfer of *Akkermansia* from mice to other commensal strains might be protective as well. Future studies could explore the role of *Akkermansia* in the context of HCC development. Finally, microbiota modulation experiments using germ-free mice would provide even more experimental precision. In these studies, it would be interesting to study whether the transfer of *Nlp6+* microbiota will eventually result in enhanced HCC development. Our current bulk RNA sequencing data clearly links bacterial translocation to fibro-inflammatory pathways as well as TF expression involved in T cell exhaustion. However, future studies including protein and histology data are warranted to substantiate these findings.

In summary, our data demonstrate that gut microbiota directly influence the hepatic inflammatory microenvironment in mice and men. An unfavorable microbiota—as seen in dysbiotic *NemoHepa*/*Nlp6−/−* —and transmissible to *NemoHepa* mice—fuel liver disease progression by promoting mMDSCs and dampening CD8+ T cells. Importantly, microbiota modulation immediately reshapes the inflammatory microenvironment providing a rational for microbiota targeted therapies. The strong association of liver tissue microbiota and hepatic transcriptomic profile in cirrhosis patients calls for larger studies to assess its diagnostic application.

**Methods**

*Mice.* Male Alb-cre-*NemoHepa*, Alb-cre-*NemoΔ* referred to as WT, Alb-cre-*NemoHepa*/*Nlp6−/−* and Alb-cre-*NemoΔ*/*Thrb−/−* of the C57B6 background were bred in the central animal facility of the hospital RWTH Aachen. *NemoHepa*/*Nlp6−/−*_mice and *NemoΔ*_ lines were generated from an initial heterozygous breeding and then separated for at least 3 generations to allow the development of the *Nlp6−/−*_ dysbiotic microbiota community. Subsequently, these two lines were kept strictly separate and we did not allow any exchange of mice or bedding material between the two lines as the microbiota related phenotype of these mice has been shown to be transmissible upon co-housing.

All mice were housed in the individually ventilated cages with access to a standard chow diet and drinking water ad libitum. Upon birth, male mice were assigned to either no treatment, FMT or ABX groups and followed up until week 13. Experiments for these age progression experiments were run and analyzed in parallel. FMT or ABX was initiated in the respective groups at 7–9 weeks of age and continued until week 13. All mice were housed at a temperature of 21–23 °C with relative humidity of 35–65% and 12 h light/dark cycle. All animal experiments were approved by the appropriate German authorities (LANUV. North Rhine-Westphalia. (AZ84-02.04.2013.A184 (C.T.), (AZ84-02.04.2013.A260 (C.T.), AZ84-02.04.2017.A 327 (C.T.), AZ84-03.04.2013.A240 (C.T.)) All mice were treated in accordance to the criteria of the German administrative panels on laboratory animal care as outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

**Cirrhosis cohort.** Human cirrhosis liver tissue specimen were taken from patients that underwent liver transplantation between 1999 and 2005 at the University Hospital Bonn (Supplemental Table 2). The human ethics committee of the University of Bonn (029/13) approved the study. Healthy surgical tissue specimen were obtained from patients who underwent clinically indicated liver resection at University Hospital Bonn or University Hospital rechts der Isar of the Technical University Munich. All patients gave written informed consent to use excess biopsy material for research purposes. The study of these pseudonymized tissue specimen has been approved by the local ethics committee RWTH Aachen University (EK 196/19).

**Depletion of microbiota with broad spectrum antibiotics.** For microbiota depletion, a broad-spectrum antibiotic cocktail (ampicillin 1 g/L, vancomycin 1 g/L, gentamycin 160 mg/L, metronidazole 1 g/L) was administered in the drinking water of 8-week-old *NemoHepa*/*Nlp6−/−* mice. To decrease the bitter taste of the antibiotics, 25 g glucose were added per liter. Antibiotic treatment was performed until week 13. Antibiotic water was replenished every second day.

**Fecal microbiota transfer.** For microbiota modulation experiments (fetal microbiota transfer, FMT), *NemoHepa* mice were treated for 5 weeks three times/week (Monday–Wednesday and Friday) via oral gavage with 200 µl of fecal dilution. To prepare this dilution, each mouse was gently centrifuged for 5 min at 350 × g to allow stool particulate to settle. The supernatant was collected and diluted 1:1 in anaerobic PBS. 200 µl of this suspension was transferred by oral gavage into recipient mice.

This is *Akkermansia muciniphila* MucT strain was isolated in the lab of Willem de Vos. It was grown as detailed by Depommier et al. was stored in Glycerol at a concentration of 2 × 10^10 CFU/100 µl at −80 °C. Immediately before gavage Akkermansia was thawed and diluted 1:2 in anaerobic PBS reduced with 0.5 g/L of L-cysteine–HCl. Mice were then gavaged with either 200 µl of this solution or anaerobic PBS.

**Bone marrow transplantation.** Bone marrow cells from WT and *Thrb−/−*_ donors were transplanted into 6-week-old WT, and *NemoHepa* recipients after ablative γ-irradiation. Recipients were radiated twice with 6 Gy with an interval of 4 h. Donors were sacrificed and femur and tibia were exposed. With a fine needle the medullary canal was flushed with Hank’s/FCS. After twice washing with Hank’s/FCS, cells were counted, and recipients received 1 × 10^6 cells via tail vein injection after the second radiation. During the first four weeks mice received antibiotic washes to minimize the danger of infection. Mice were sacrificed 8 weeks after transplantation.

**Intestinal permeability in vivo.** Isothiocyanate conjugated dextran (FITC-dextran, molecular mass 4.0 kDa, Uppsala, Sweden) dissolved in PBS at a
concentration of 200 mg/ml was administered to mice (10 mg/kg body weight) by oral gavage. 4 h after gavage the mice were sacrificed under general anesthesia by isoflurane. Blood samples were collected from inferior vena cava and immediately stored at 4 °C in the dark. Concentration of FITC in serum was determined by spectrophotofluorometry at an excitation wavelength of 485 nm (20 nm band width) and an emission wavelength of 528 nm (20 nm band width). Relative induction of FITC signal relative to age-matched WT control mice was calculated.

H&E—histology. Hematoxylin and eosin (H&E) staining was performed as previously described18. Briefly, tissue sections fixed in 4% paraformaldehyde (PFA) were cut into 2 µm sections. Tissue sections were deparaffinized and rehydrated. Next samples were stained with Mayer’s Hematoxylin solution for 1 min. Samples were rinsed in tap water for 15 min, placed in distilled water for 30 s, placed in 95% alcohol for 30 s and next counterstained in Eosin solution for 1 min. Finally, samples were dehydrated and mounted with coverslips using the Roti® Histokit.

Sirus Red staining. Liver fibrosis development was studied using the following protocol. First, tissue sections embedded in paraffin were stained with Sirius red. For this purpose, tissue sections were deparaffinized by heating the slides at 65 °C for 15 min, followed by 2 × 5 min in xylene, and rehydration by introducing a descending concentration of ethanol (100% ethanol and 96% ethanol, 5 min in 70% ethanol and distilled water). Tissue sections were then placed for 45 min in a 0.1% Sirius red solution, followed by 2 × 15 s incubation in 0.5% glacial acetic acid. Finally, sections were dehydrated by ascending alcohol incubations (2 min 96%, 2 × 5 min 100% ethanol and 2 × 5 min xylene). Mounting of Tissue sections was performed with coverslips using the Roti® Histokit.

Immunohistochemistry staining. Five µm thick formalin-fixed, paraffin-embedded liver tissue sections were used to perform immunohistochemical stainings. First, the tissue sections were deparaffinized and rehydrated. For Antigen recovery, sections were heated in a pressure cooker in citrate buffer (pH 6.0). The tissue sections were then immersed in H2O2 solution (0.3% in methanol) for 10 min to block the endogenous peroxidases. To further block unspecific binding, the tissue sections were incubated in 1% bovine serum albumin in PBS for 2 h. Blocking was followed by incubation of the tissue sections overnight with the primary antibodies (Supplementary Table 6) at 4 °C in a humid chamber. After primary antibody incubation tissue sections were washed thoroughly in PBS. Next, the tissue sections were incubated with appropriate biotinylated peroxidase-conjugated secondary antibodies (Supplementary Table 6) in a humid chamber at room temperature. Visualization of target signals was achieved by staining with 3,3’-diaminobenzidine solution (Vector Laboratories, Burlingame, CA, USA) for 2–5 min under the microscope. The nuclei were visualized by hematoxylin counterstaining. Finally, dehydrated sections were mounted in increasing concentrations of ethanol and mounted in Entellan.

Immunofluorescence staining. After collection tissue specimens were immediately embedded in Tissue-Tek. Using a cryotome, tissues were cut into 5 µm-thick sections and stored at −80 °C. Slides were air-dried for 30 min at RT followed by 4% PFA fixation. Next, tissue samples were encircled using a hydrophobic pen and blocked with 1% BSA in PBS for 1 h at RT in a humidity chamber. After blocking, samples were incubated with the primary antibodies (Supplementary Table 6) at 4 °C in a humidity chamber overnight. Samples were washed thoroughly in PBS and then incubated with the secondary antibodies (Supplementary Table 6) for 1 h in a humidity chamber. After incubation, sections were washed again thoroughly in PBS. Finally, sections were mounted in a DAPI (Vector Laboratories, Burlingame, CA, USA) aqueous medium to counterstain the nuclei. Staining of mucus and gut bacteria was performed according to an established protocol2. Briefly, colon tissue sections containing feces were fixed using the Carnoy fixation method (60% absolute methanol, 30% chloroform, 10% glacial acetic acid). After paraffin embedding, mucus and gut bacteria were stained with an anti-Muc2 primary antibody and a fluoresce in situ hybridization (FISH) probe against eubacteria (16S rDNA: 5’-GCTGCGCTCCTCCTTAGGACT-3’).

Flow cytometry analysis of intrahepatic leukocytes. Same amounts of livers were digested by collagenase type IV for 1 h at 37 °C (Worthington Biochemical Corporation, Lakewood, NJ, USA) and intrahepatic immune cells were isolated by multiple differential centrifugation steps as detailed2. Cell isolates were incubated with blocking buffer for 30 min at 37 °C to block the unspecific binding sites of cell surface, then divided into two subgroups and stained with fluorochrome-conjugated antibodies either for myeloid cells FcITT Rat anti-Mouse Ly-6-G (561105; BD bioscience, Heidelberg, Germany), CD11b Monoclonal Antibody (M1/70), PE (12-0112-82, Thermo Fisher Scientific, Waltham, MA, USA), CD11c Monoclonal Antibody (10F11), APC, Biolegend, San Diego, CA, USA), F4/80 Monoclonal Antibody (BM8), PE—Cyanine7 (25–4801-82, Thermo Fisher Scientific, Waltham, MA, USA), PerCP-Cy5.5 Rat Anti-Mouse Ly-6-G and Ly-6C (552093, BD bioscience, Heidelberg, Germany), APC-Cy7™ Rat Anti-Mouse CD45 (557659, BD bioscience, Heidelberg, Germany). For lymphocytes CD45+ or lymphocytes CD45− the following antibodies were used: Anti-CD11c (14G2a), APC-CD11c (17-0031-83, Thermo Fisher Scientific, Waltham, MA, USA), CD4 Monoclonal Antibody (GR1.5), PE (12-0041-83, Thermo Fisher Scientific, Waltham, MA, USA) CD14 Monoclonal Antibody (53-6.7), FITC (11-0081-85, Thermo Fisher Scientific, Waltham, MA, USA), PerCP-Cy5.5 Rat Anti-Mouse CD19 (551901, BD bioscience, Heidelberg, Germany). Data were analyzed by the FlowJo software (Ashland, OR, USA).

DNA isolation and 16S rRNA amplicon sequencing. For 16S rRNA gene sequencing, DNA was isolated from fecal samples using an established protocol24. Briefly, each sample (around 200 mg) was resuspended in 500 µl of extraction buffer (200 mM Tris, 20 mM EDTA, 200 mM NaCl, pH 8.0), 200 µl of 20% SDS. 500 µl of chloroform/isoamyl alcohol (24:24:1) and 100 µl of 0.5 M Tris/NaOH/silica beads (0.1 mm diameter). Samples were homogenized twice with a bead beater (BioSpec, Bartlesville, OK, USA) for 2 min. After precipitation of DNA, crude DNA extracts were resuspended in TE Buffer with 100 µg/ml RNase I and column purified to remove PCR inhibitors. Amplification of the V4 region (F515/R806) of the 16S rRNA gene was performed according to previously described protocols25. Briefly, for 16S rRNA amplicon sequencing 25 ng of DNA were used per PCR reaction (30 µl). The PCR conditions consisted of initial denaturation for 30 s at 98 °C, followed by 25 cycles (10 s at 98 °C, 20 s at 55 °C, and 20 s at 72 °C). Each sample was amplified in triplicates and subsequently pooled. After normalization PCR amplicons were sequenced on an Illumina MiSeq platform (PE250).

16S rRNA analysis was conducted based on a previously described computational workflow29. In brief, obtained reads were assembled, quality controlled and clustered using Usearch41 (http://www.drive5.com/usearch/). Next, reads were merged using ‘-use_art_size’ and only reads with a quality score of 70% and above (‘-fastx_maxee 1’), minimum read length 200 bp. The OTU and representative sequences were determined using the UPARSE algorithm32, followed by taxonomy assignment using a curated Silva database v12838 and the RDP Classifier39 with a sequence identity cut-off of 80%. The OTU absolute abundance table and mapping file were used for statistical analyses and data visualization in the R statistical programming environment (http://www.project.org) package phyloseq80. The permutational multivariate ANOVA (ADONIS test) was performed in R. Factors with p value < 0.05 were considered as significant. Differential abundance analysis (DAA) was performed using a consensus approach based on multiple methods (DSEq2, LEfSe, and ALDEKx) to help ensure robust biotransformation and meta-transcriptome analysis was performed using the parameters, test = “Wald”, fitType = “parametric”, alpha = 0.0132. OTUs were considered significantly DA between genotypes if their adjusted p-value was <0.05 and if the estimated 2-fold change was ≥2 (Love et al., 2014, McMurdie and Holmes, 2014). LeSe was performed using the R wrapper helper (keleSe) with the following parameters keulsthreshold = “0.05”, wilcox.threshold = “0.05”, ldah.threshold = “2.5”. ALDEKX33 was performed using default settings, OTUs were considered significantly DA between controls if (w/beh Expected Benjamini–Hochberg corrected p value of Welch’s t test) or (w/beh Expected Benjamini–Hochberg corrected p value of Wilcoxon test) was <0.05.

16S rDNA quantitation and taxonomic profiling in liver tissues. Microbial DNA was isolated from frozen liver biopsies with a protocol designed to minimize the risk of contamination by the environment or experimenters as previously described2. Negative controls consisting of molecular grade water were placed in separate isolation tubes during the isolation process and processed simultaneously throughout the protocol. DNA was amplified using real-time polymerase chain reaction (qPCR) amplification using universal 16S primers targeting the hypervariable V3 region of 16S rDNA sequences were determined using the UPARSE algorithm77, followed by taxonomy assignments and species-level abundance estimation using the R application “qiime”283. A LDEKX283 was performed using “qpcr” software with the following parameters keulsthreshold = “0.05”, w/beh Expected Benjamini–Hochberg corrected p value of Welch’s t test or (w/beh Expected Benjamini–Hochberg corrected p value of Wilcoxon test) was <0.05.

In line with our previous data, these numerous quality controls demonstrate that potential bacterial contamination was well contained and had a negligible impact on the taxonomic profiles of the samples in our study33,85,86.
added to separate the phases, the upper aqueous phase was transferred into a new collection tube. 500 µl isopropanol were added and the samples remained at RT for 15 min. Afterwards, the RNA was pelleted by centrifugation at 13,000 × g for 10 min at 4 °C, the supernatant was discarded, and the pellets were washed twice with ethanol 70%. Next pellets were air dried and 300 µl DEPC water was used for resuspension. For transcription 1 µg of the isolated mRNA were used and reverse transcription into cDNA was performed using Omniscript™ RT Kit (Cat. No. 205123, QIAGEN, Venlo, The Netherlands) according to the manufacturer’s protocol. Real-time PCR reactions were performed with Real-Time PCR System Quant studio 6 Flex (Thermo Fisher Scientific, Waltham, MA, USA) and Fast SYBR® GreenER Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer’s recommendations. The primers were diluted 1:10 fold or 1:58 respectively. All primer sequences are listed (Supplemental Table 7). The Quant Studio Flex software (Thermo Fisher Scientific, Waltham, MA, USA) was used for analysis. In the following the relative mRNA expression was calculated with the 2−ΔΔCT method comparing target gene expression to the GAPDH housekeeping gene.

Library preparation and mRNA sequencing. After quality control with the Agilent Tape Station 4200 RNA ScreenTape Analysis and quantification with the QuantFluor RNA System (Promega), the library preparation was done according to the manufacturer’s protocol with the Illumina TruSeq Stranded Total RNA Library Prep Gold kit with IDT for Illumina—TruSeq RNA UD Indexes. Sequencing of the library pool was done on one lane using the Illumina NovaSeq 6000 54 Reagent Kit (200 cycles) on the NovaSeq X 4 Lane.ape. Differences in cell type enrichment between healthy and cirrhotic patients were computed with a t-test. To adjust p-values for multiple hypothesis testing we computed the false discovery rate (FDR).

In-vitro MDSC assay

MDSC isolation. MDSCs were isolated with Myeloid-Derived Suppressor Cell Isolation Kit (mouse; 130-094-538, Miltenyi, Wuppertal, Germany) from liver. After preparing a single cell suspension, the cell number was determined. Cell suspension was centrifuged at 300 × g for 10 min at 4 °C. Supernatant was aspirated completely and up to 107 cells were resuspended in 40 µl buffer and 10 µl of Anti-Gr-1-Biotin (Biolegend, San Diego, CA, USA) in 4 µl of buffer. 200 µl of BSA diluted in TBST 0.5% were added, mixed, and incubated for 10 min in the refrigerator (2–8 °C). Cells were washed by adding 5–10 ml of buffer per 106 cells and centrifuged at 300 × g for 10 min at 4 °C. Supernatant was aspirated completely and up to 106 cells were resuspended in 800 µl of buffer. 200 µl of Anti-Biotin MicroBeads were added, mixed, and incubated for 15 min in the refrigerator (2–8 °C). Cells were washed by adding 10–20 ml of buffer per 106 cells and centrifuged at 300 × g for 10 min at 4 °C. Supernatant was aspirated completely and up to 106 cells were resuspended in 500 µl of buffer. LS Column was placed in the magnetic field of a suitable MACS Separator. Column was rinsed with 3 ml of buffer and cell suspension applied onto the column. Flow-through was collected which contained the unlabeled cells. Column was washed with 3 × 3 ml of buffer. The unlabeled cells which passed through were combined with the eluent from step 3; These cells represented the unlabeled pre-enriched Gr-1dimLy-6G− cell fraction. Column was removed from separator and a collection tube was placed under. 5 ml of buffer was added onto the column and the magnetically labeled cells were flushed out by firmly pushing the plunger into the column. These cells represented the labeled Gr-1brightLy-6G+ cell fraction.

The unlabeled pre-enriched Gr-1dimLy-6G− cell fraction was centrifuged at 300 × g for 10 min at 4 °C. Supernatant was aspirated completely and up to 106 cells were resuspended in 400 µl buffer. 100 µl of Anti-Gr-1-Biotin per 106 cells was added, mixed, and incubated for 10 min at 4 °C. Per 106 cells 5–10 µl of buffer were added and centrifuged at 300 × g for 10 min at 4 °C. Supernatant was aspirated completely and up to 106 cells were resuspended in 900 µl of buffer. In addition, 100 µl of Streptavidin MicroBeads were added, mixed, and incubated for 15 min in 4 °C. Trails were combined with the eluent from step 3; These cells represented the unlabeled pre-enriched Gr-1dimLy-6G− cell fraction. Column was removed from separator and a collection tube was placed under. 1 ml of buffer was added onto the column and the magnetically labeled cells were flushed out by firmly pushing the plunger into the column. These cells represented the labeled Gr-1brightLy-6G+ cell fraction.

Cell types enrichment with xCell. xCell is a tool that performs sample-wise cell type classifications from gene expression data and returns for each TF a normalized enrichment score (NES) that orthEA uses the statistical method viper to access the TF activity from gene expression data and returns for each TF a normalized enrichment score (NES) that we consider a proxy for TF activity.

T cell isolation. T cells were isolated with (mouse; 130-095-130, Miltenyi, Wuppertal, Germany) from spleen. After preparing a single cell suspension, cell number was determined. 30 µl of buffer and 20 µl of Anti-Biotin MicroBeads per 106 total cells were added, mixed, and incubated for 10 min at 4 °C. LS Columns were placed in the magnetic field and 3 ml of buffer added onto the column. Cell suspension was applied onto the column and flow through collected. Column was washed 3 × 3 ml and flow through collected.
In vitro T cell assay. U bottom 96 wells were coated with 2 µg/ml CD3 antibody (6-0032-85 (Clone 17A2; 1 mg/ml) Thermo Fisher Scientific, Waltham, MA, USA) and incubated for 2 h at 37 °C. Plates were washed three times with PBS prior to the start of the assay. T cells (10^5 cells) were incubated with gMDSCs or mMDSCs in the following ratios: 1:0, 1:1, 1:2 or 1:4. Additionally, 10 µg/ml of CD28 (553294 (Clone 27.51; 1 mg/ml) BD bioscience, Heidelberg, Germany) was added per well. Proliferation was analyzed using a FACS Fortessa (BD, Bioscience, Heidelberg, Germany). Data were analyzed with the Flowjo software (Ashland, OR, USA).

**Measurement of routine serum parameters.** Routine serum parameters alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH) and alkaline phosphatase (AP) were measured in the central laboratory of clinical chemistry in RWTH Aachen University Hospital.

**Quantification and statistical analyses.** For comparisons of two groups, significance was tested by unpaired two-tailed Student’s t test. In case of more than two groups, we employed one-way ANOVA followed by Tukey-test with adjusted p-value for multiple comparisons. For not normally distributed data, two groups were compared using Wilcoxon–Mann–Whitney–Test and in case of more than two groups Kruskal–Wallis test with Dunn–Bonferroni-Test was used. Data were considered significant between experimental groups as: *p < 0.05. **p < 0.01 or ***p < 0.001.

**Statistical analyses of 16S microbiota data was performed using R version 34.3 (2017-11-30) (http://www.rproject.org) and the packages 'phyloseq', and 'ggplot2' of. The permutational multivariate analysis of variance test (ADONIS) and analysis of similarities (ANOSIM) were computed with 999 permutations. For two groups, we employed one-way ANOVA followed by Tukey-test with adjusted p-value for multiple comparisons. For not normally distributed data, two groups were compared using Wilcoxon–Mann–Whitney–Test and in case of more than two groups Kruskal–Wallis test with Dunn–Bonferroni-Test was used. Data were considered significant between experimental groups as: *p < 0.05. **p < 0.01 or ***p < 0.001.

**Statistical analyses of 16S microbiota data was performed using R version 34.3 (2017-11-30) (http://www.rproject.org) and the packages 'phyloseq', and 'ggplot2' of. The permutational multivariate analysis of variance test (ADONIS) and analysis of similarities (ANOSIM) were computed with 999 permutations. For two groups, we employed one-way ANOVA followed by Tukey-test with adjusted p-value for multiple comparisons. For not normally distributed data, two groups were compared using Wilcoxon–Mann–Whitney–Test and in case of more than two groups Kruskal–Wallis test with Dunn–Bonferroni-Test was used. Data were considered significant between experimental groups as: *p < 0.05. **p < 0.01 or ***p < 0.001.

**Statistical analyses of 16S microbiota data was performed using R version 34.3 (2017-11-30) (http://www.rproject.org) and the packages 'phyloseq', and 'ggplot2' of. The permutational multivariate analysis of variance test (ADONIS) and analysis of similarities (ANOSIM) were computed with 999 permutations. For two groups, we employed one-way ANOVA followed by Tukey-test with adjusted p-value for multiple comparisons. For not normally distributed data, two groups were compared using Wilcoxon–Mann–Whitney–Test and in case of more than two groups Kruskal–Wallis test with Dunn–Bonferroni-Test was used. Data were considered significant between experimental groups as: *p < 0.05. **p < 0.01 or ***p < 0.001.
39. Roychoudhuri, R. et al. The transcription factor BACH2 promotes tumor

51. Ma, J. et al. PD1Hi CD8

ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-31312-5
Acknowledgements

We thank Ms. Sonja Strauch and Ms. Bettina Jansen—University Hospital RWTH Aachen, Aachen, Germany for their excellent technical assistance. We thank the members of the Trautwein lab and Department of Medicine III for valuable discussions and input. We thank Mathias Hornef for critical comments and suggestions and Thomas Clavel and Theresa Streidl for providing help with A. muciniphila transfer experiments. This study was supported by the German Research Foundation Tr 285/10-2 and CRC1382 (Project-ID 403224013) to C.T., The German Cancer Aid (Deutsche Krebshilfe) to C.T. The HDHL-INTIMIC Di-Mi-Liv to C.T., K.M.S., and H.U.M., BMBF Knowledge Platform on Food, Diet, Intestinal Microbiomics and Human Health to C.T. and K.M.S., the SFB 985 project C3 to C.T., the Interdisciplinary Centre for Clinical Research (START Grant #691438) within the Faculty of Medicine at RWTH Aachen University, the Helmholtz Association (T.S.), the Swedish Research Council to H.U.M., the German National Academic Foundation (to C.E. and K.M.S.)

Author contributions

K.M.S., A.M. performed most of the experiments, analyzed most of the data, K.M.S. designed the study, drafted the MS; W.G., L.S.C., C.E. K.K. helped with the experiments and data analyses, E.J.C.G. performed microbiota analyses, C.H.H. performed mRNA Seq. analysis, C.V.S., P.S., R.S. and T.H.W reviewed the study and gave important intellectual input, H.U.M. and E.L. critically reviewed the study and MS, B.L. performed hepatic microbiota analyses, J.S.-R. supervised mRNA Seq. analyses, W. de V. supervised A. muc. experiments, reviewed and discussed the MS, T.S. supervised intestinal microbiota analyses and revised the MS, T.S. supervised intestinal microbiota analyses and revised the MS, J.T. gave important intellectual input, provided clinical tissue specimen, supervised the clinical study, revised the MS, C.T. designed the study, supervised the experiments and data analyses, revised the MS, provided funds.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-31312-5.

Correspondence and requests for materials should be addressed to Christian Trautwein.

Peer review information Nature Communications thanks David Adams, Guillaume Meric and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.